Miglustat Patent Expiration
Miglustat was first introduced by Actelion Pharmaceuticals Us Inc
Miglustat Patents
Given below is the list of patents protecting Miglustat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opfolda | US12246062 | Recombinant human acid alpha-glucosidase | Sep 16, 2038 | Amicus Therap Us |
| Opfolda | US10857212 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | Aug 12, 2037 | Amicus Therap Us |
| Opfolda | US11278601 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | Dec 29, 2036 | Amicus Therap Us |
| Opfolda | US12414985 | Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease | Dec 29, 2036 | Amicus Therap Us |
| Opfolda | US10208299 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US10961522 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US11753632 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US10512677 | High concentration alpha-glucosidase compositions for the treatment of pompe disease | Mar 07, 2033 | Amicus Therap Us |
| Opfolda | US11278599 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | Mar 07, 2033 | Amicus Therap Us |
| Opfolda | US12419937 | High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease | Mar 07, 2033 | Amicus Therap Us |
| Zavesca | US5525616 | Method of inhibiting glycolipid synthesis |
Jun 11, 2013
(Expired) | Actelion |
| Zavesca | US5472969 | Method of inhibiting glycolipid synthesis |
May 13, 2013
(Expired) | Actelion |
Miglustat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Miglustat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | Amicus Therapeutics | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |